Melbourne-based Patrys (ASX:PAB), a therapeutic antibody development company, has announced new pre-clinical animal data for its lead candidate, PAT-DX1.
Investors welcomed the announcement by boosting the company's share price by 50 per cent. The company's share price had settled up by over 20 per cent at midday.
The company said the new data provides further support that PAT-DX1 could suppress tumour growth in patients with triple-negative breast cancer (TNBC) brain metastases.
The company also said the study broadens understanding of the dosing and impact of PAT-DX1 on TNBC brain metastases.
PAT-DX1 was able to cross the blood-brain barrier and no toxicity was observed. As a single agent, it caused similar tumour growth suppression to that of low dose radiation treatment, while the combination of PAT-DX1 and radiation treatment resulted in significantly more tumour suppression than either treatment alone.
“We are delighted to be able to report the confirmation that PAT-DX1 crosses that blood-brain barrier and shows single agent efficacy in a sophisticated animal model of TNBC brain metastases," said Patrys CEO and managing director, Dr James Campbell.
"We are not aware of any other antibody that brings together these transformative attributes. We are particularly excited to report that a limited dose of PAT-DX1 enhanced the efficacy of low dose radiation therapy.
"This study represents another substantial advance in our understanding of the dosing and the possible clinical applications for PAT-DX1. The Company is excited by the prospects that our lead candidate may have in improving patient outcomes where there remains a large unmet medical need for TNBC brain metastases.”